Borderline or Atypical ALK Negative Tumors Deserve Second LookBorderline or Atypical ALK Negative Tumors Deserve Second Look
Current criteria for identifying non-small cell lung cancers that might respond to crizotinib might be missing some patients, a new study hints. Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Borderline Tumor | Cancer | Cancer & Oncology | Health | Hematology | Non-Small Cell Lung Cancer | Study